Tibor Keler Buys 115,000 Shares of Celldex Therapeutics

Tibor Keler, the Executive VP & Chief Scientific Officer at Celldex Therapeutics, Inc. (NasdaqCM: CLDX), recently purchased 115,000 shares of the company. The transaction, completed on June 25, 2026, reflects a significant insider move, although the specific transaction price was not disclosed.

Celldex Therapeutics, Inc. Stock Down 9.9%

Shares of Celldex Therapeutics traded near $35.26 on Tuesday. The company, with a market cap of about $2.77 billion, operates in the biotechnology sector. It has a forward P/E ratio that isn't meaningful due to negative earnings per share of -$4.27. The stock shows a 52-week range between $19.52 and $35.79, with a 50-day moving average of $32.10 and a 200-day moving average of $28.27. The company maintains a strong financial position with a current ratio of 8.92 and a quick ratio of 8.78.

Insider Buying and Selling at Celldex Therapeutics, Inc.

Alongside Tibor Keler, other insiders made notable purchases on June 25, 2026. Ronald Pepin, Senior VP & CBO, acquired 20,000 shares, while Denice Torres and Garry Arthur Neil each bought 26,000 shares. Samuel Bates Martin, the Senior VP and CFO, purchased 93,000 shares. Additionally, Margo Heath-Chiozzi and Sarah Cavanaugh, both Senior VPs, bought 95,000 shares each. None of these transactions were part of a pre-arranged trading plan.

Analysts Set New Price Targets

Analysts have been active in evaluating Celldex. On June 15, 2026, HC Wainwright & Co. reiterated a buy rating with a $42 target. UBS maintained its buy rating with a $45 target on June 10, 2026. Other firms like Wells Fargo and Barclays have also maintained buy ratings with targets of $54 and $48, respectively. The consensus remains strong buy, with a mean target price of $57.53 based on 15 analyst opinions.

About Celldex Therapeutics

Celldex Therapeutics, Inc. is a biopharmaceutical company headquartered in Hampton, New Jersey. It focuses on developing therapeutic antibodies for severe inflammatory, allergic, and autoimmune diseases. The company is known for its clinical programs, including Barzolvolimab and CDX-622, aimed at treating conditions like chronic urticarias and prurigo nodularis. Led by CEO Anthony S. Marucci, Celldex employs approximately 198 people.

Bottom Line

The insider buying activity at Celldex Therapeutics suggests confidence in the company's future prospects. While insider transactions provide insight, they are not necessarily indicative of future stock performance. Investors often track such activities as part of their broader analysis. As always, remember that 13F filings and insider reports are backward-looking and may not reflect the current status.